J&J’s Janssen Partners for Hepatitis B TreatmentsBy
Bioaster, a technology research institute focused on areas in microbiology and infectious diseases, has formed a joint collaboration with the Cancer Research Center of Lyon and Janssen-Cilag SAS, one of the Janssen pharmaceutical companies of Johnson & Johnson, to support the preclinical research and development of immunotherapeutic treatments for chronic hepatitis B virus (HBV). The two-year project pact aims to develop a predictive model by evaluating a preclinical model’s susceptibility to HBV and its suitability as an human model.
The collaboration will be jointly coordinated by Janssen France and Johnson and Johnson Innovation. The financial details of the deal were not disclosed.